Payment overview · 2025
General Payments
$699.70
16 reported records · 9 companies
Healthcare provider profile · identity verified
Anusuya Jeyakumar, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · TRENTON, NJ · NPI 1447453329
Verified facts
What the public records show
CMS Open Payments records show Anusuya Jeyakumar, MD received $699.70 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Jardiance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $250.54 | 35.8% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $185.22 | 26.5% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $106.33 | 15.2% | 1 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $49.68 | 7.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $35.63 | 5.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.70 | 3.5% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $16.39 | 2.3% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $16.09 | 2.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.12 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $699.70 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $185.22 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $127.76 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $122.78 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $106.33 | 1 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $49.68 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $35.63 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.70 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 191 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
191 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
191 | 27 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1432 | 235 |
| Amlodipine Besylate | Amlodipine Besylate | 1145 | 194 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1000 | 140 |
| Furosemide | Furosemide | 780 | 129 |
| Metoprolol Succinate | Metoprolol Succinate | 670 | 119 |
| Losartan Potassium | Losartan Potassium | 667 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 563 | 108 |
| Eliquis | Apixaban | 501 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 483 | 98 |
| Potassium Chloride | Potassium Chloride | 404 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 384 | 59 |
| Promethazine Hcl | Promethazine Hcl | 378 | 79 |
| Gabapentin | Gabapentin | 358 | 73 |
| Donepezil Hcl | Donepezil Hcl | 353 | 52 |
| Metformin Hcl | Metformin Hcl | 314 | 52 |
| Omeprazole | Omeprazole | 306 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 275 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 271 | 40 |
| Lisinopril | Lisinopril | 262 | 44 |
| Divalproex Sodium | Divalproex Sodium | 256 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 242 | 45 |
| Carvedilol | Carvedilol | 232 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 228 | 45 |
| Januvia | Sitagliptin Phosphate | 226 | 32 |
| Memantine Hcl | Memantine Hcl | 213 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 212 | 46 |
| Montelukast Sodium | Montelukast Sodium | 210 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 207 | 46 |
| Meloxicam | Meloxicam | 195 | 33 |
| Tramadol Hcl | Tramadol Hcl | 195 | 45 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 194 | 26 |
| Jardiance | Empagliflozin | 191 | 27 |
| Mirtazapine | Mirtazapine | 189 | 41 |
| Sertraline Hcl | Sertraline Hcl | 187 | 38 |
| Cefuroxime | Cefuroxime Axetil | 173 | 121 |
| Prednisone | Prednisone | 171 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 169 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 167 | 42 |
| Simvastatin | Simvastatin | 166 | 30 |
| Glimepiride | Glimepiride | 153 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 150 | 20 |
| Xarelto | Rivaroxaban | 147 | 17 |
| Azithromycin | Azithromycin | 146 | 93 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 140 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 139 | 26 |
| Levetiracetam | Levetiracetam | 136 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 136 | 27 |
| Alprazolam | Alprazolam | 132 | 46 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 128 | 22 |
| Latanoprost | Latanoprost | 121 | 24 |
| Clonidine Hcl | Clonidine Hcl | 117 | 19 |
| Trazodone Hcl | Trazodone Hcl | 117 | 26 |
| Famotidine | Famotidine | 111 | 29 |
| Finasteride | Finasteride | 111 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 110 | 24 |
| Ezetimibe | Ezetimibe | 110 | 26 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 99 | 27 |
| Valsartan | Valsartan | 98 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 95 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 33 |
| Ammonium Lactate | Ammonium Lactate | 91 | 38 |
| Lorazepam | Lorazepam | 90 | 19 |
| Myrbetriq | Mirabegron | 90 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 18 |
| Vascepa | Icosapent Ethyl | 88 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 76 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 75 | 14 |
| Bupropion Xl | Bupropion Hcl | 73 | 13 |
| Levofloxacin | Levofloxacin | 72 | 43 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 71 | 17 |
| Loperamide | Loperamide Hcl | 71 | 29 |
| Celecoxib | Celecoxib | 70 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 70 | 35 |
| Risperidone | Risperidone | 68 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 13 |
| Ibuprofen | Ibuprofen | 67 | 20 |
| Alendronate Sodium | Alendronate Sodium | 66 | 20 |
| Midodrine Hcl | Midodrine Hcl | 66 | 12 |
| Spironolactone | Spironolactone | 66 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 63 |
| Cephalexin | Cephalexin | 63 | 48 |
| Buspirone Hcl | Buspirone Hcl | 61 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 60 | 12 |
| Naproxen | Naproxen | 56 | 27 |
| Nystop | Nystatin | 56 | 34 |
| Allopurinol | Allopurinol | 55 | 11 |
| Torsemide | Torsemide | 55 | suppressed |
| Tradjenta | Linagliptin | 55 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 53 | 26 |
| Propranolol Hcl | Propranolol Hcl | 53 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 52 | 14 |
| Olanzapine | Olanzapine | 52 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 52 | suppressed |
| Bumetanide | Bumetanide | 51 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 11 |
| Fenofibrate | Fenofibrate | 48 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Irbesartan | Irbesartan | 47 | suppressed |
| Baclofen | Baclofen | 46 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 31 |
| Lansoprazole | Lansoprazole | 44 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 44 | suppressed |
| Amoxicillin | Amoxicillin | 43 | 18 |
| Atenolol | Atenolol | 43 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 43 | suppressed |
| Nystatin | Nystatin | 43 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 43 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | suppressed |
| Glipizide Er | Glipizide | 42 | suppressed |
| Mupirocin | Mupirocin | 42 | 20 |
| Entresto | Sacubitril/Valsartan | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Clozapine | Clozapine | 40 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 39 | suppressed |
| Nifedipine Er | Nifedipine | 38 | 11 |
| Repaglinide | Repaglinide | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 20 |
| Clobetasol Propionate | Clobetasol Propionate | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 24 |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Xtampza Er | Oxycodone Myristate | 35 | suppressed |
| Gemtesa | Vibegron | 34 | suppressed |
| Rivastigmine | Rivastigmine | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 33 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Comfort Ez Pro Safety Pen Ndl | Pen Needle, Diabetic, Safety | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Methotrexate | Methotrexate Sodium | 31 | suppressed |
| Carbamazepine | Carbamazepine | 30 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 29 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 29 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 29 | suppressed |
| Timolol Maleate | Timolol Maleate | 28 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Multaq | Dronedarone Hcl | 26 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 26 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 24 | suppressed |
| Nyamyc | Nystatin | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Methimazole | Methimazole | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Tobramycin | Tobramycin | 22 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 19 | 19 |
| Silodosin | Silodosin | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | 11 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Dexamethasone | Dexamethasone | 15 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Acarbose | Acarbose | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Terconazole | Terconazole | 14 | suppressed |
| Alogliptin | Alogliptin Benzoate | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Mirabegron Er | Mirabegron | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Cefadroxil | Cefadroxil | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lorazepam Intensol | Lorazepam | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 11 | suppressed |
| Lasix | Furosemide | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $699.70 · 16 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, BREZTRI, GEMTESA, JARDIANCE, MOUNJARO, NUPLAZID, Ohtuvayre, YUPELRI, Zunveyl | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error